The subscription period in Pharmacolog's rights issue of units starts today
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE FURTHER REGISTRATION OR ANY OTHER MEASURES.
Today, 26 June, 2023, the subscription period begins in Pharmacolog i Uppsala AB's (publ) ("Pharmacolog" or the "Company") rights issue of units consisting of shares and warrants (the "Rights Issue"), which the board of directors resolved on 14 May 2023 and was approved at the extraordinary general meeting on 16 June, 2023. The subscription period in the Rights Issue runs from and including 26 June, up to and including 10 July, 2023. However, note that some banks and nominees may have an earlier deadline for subscription in the Rights Issue. Shareholders should therefore check with their bank or nominee if they have an earlier deadline for subscription.
- 21 June 2023: Record date for obtaining unit rights. Shareholders who are registered in the share register kept by Euroclear Sweden AB on this day, receive unit rights for participation in the Rights Issue.
- 26 June 2023 - 10 July 2023: Subscription period for the Rights Issue
- 26 June 2023 - 5 July 2023: Trading with unit rights on Nasdaq First North Growth Market
- 26 June 2023 - week 29, 2023: Trading with BTU on Nasdaq First North Growth Market
- 12 July 2023: Estimated date for publication of issue results
Subscription with preferential rights
The shareholders who, on the record date of 21 June, 2023, were registered in the share register maintained by Euroclear Sweden AB ("Euroclear") and on behalf of the Company, directly registered shareholders, receive a pre-printed issue report with attached payment advice from Euroclear. In the event that a different number of unit rights than those stated in the preprinted issue report are used for subscription the special application form, which is available on the Company's website http://pharmacolog.com/ and Mangold's website emission.mangold.se, shall be used as a basis for subscription through cash payment.
Shareholders whose holdings of shares in the Company were nominee-registered with a bank or other nominee on the record date do not receive an issue report or a special application form from Euroclear. Subscription and payment must then instead take place in accordance with instructions from the respective trustee.
Subscription without preferential rights
Notification of subscription without preferential rights by a nominee is made in accordance with instructions from the respective nominee. For subscription through an endowment insurance or an investment savings account, please contact your nominee. Application for subscription without preferential rights in other respects is done by sending an application form by e-mail to Mangold or alternatively by electronic subscription with Bank ID on Mangold's website. Application form and electronic subscription are available on Mangold's website emission.mangold.se.
Mangold Fondkommission AB is financial adviser to Pharmacolog in connection with the Rights Issue. Eversheds Sutherland Advokatbyrå AB is legal adviser to the Company in connection with the Rights Issue.